To explore the cost-effectiveness of quetiapine, aripiprazole or olanzapine in Russian Federation (RF) patients with bipolar disorder (BPD) depression episodes. METHODS: A cost-effectiveness analysis (CEA) was developed to estimate the cost-effectiveness of quetiapine compared with aripiprazole or olanzapine. CEA was undertaken from RF health care perspective using discount rate of 5%. The time horizon of the analysis was ne year for using preventive relapse rates and five years for QALY. Direct health care expenses associated with bipolar disorder and resulting follow-up costs were calculated using general tariff agreement of Russian obligatory insurance system and official national statistics. For reference, accepted exchange rate was 1 EUR = 40 RUB. RESULTS: Taking into account rates of prevented relapse following costeffectiveness ratios (CER) were obtained: 156,915 RUB (3,923 EUR) in quetiapine group, 429,362 RUB (10,734 EUR) in aripiprazole group and 221,879 RUB (5,547 EUR) in olanzapine group. Using QALY values CER were accounted for: 185,236 RUB (4,631 EUR) in quetiapine group, 478,433 RUB (11,961 EUR) in aripiprazole group and 254,100 RUB (6,353 EUR) in olanzapine group. CONCLUSIONS: Quetiapine in the treatment of BPD depression episodes is a dominant compared with aripiprazole or olanzapine.
OBJECTIVES:
To assess the efficiency of the atypical antipsychotics used to reduce relapses in bipolar disorder, taking into account costs and effectiveness (measured as QALY). METHODS: The Russian health care system perspective and a 5 year temporal horizon have been used. An annual discount rate assumed was of 5%. Taking into account the last literature review on bipolar disorder, four fundamental aspects related with bipolar disorder management were analyzed: relapse rates, inpatient treatment, outpatient treatment and hospitalization rates. The health care direct costs corresponding to the drug acquisition costs have been analyzed together with the costs of inpatient diagnostics, costs of inpatient treatment and costs of hospitality relapses (stay and drug cost) updated with data from Russian health care system. RESULTS: Quetiapine or risperidone treatment presents the lower total costs (€13,562 and €13,097 respectively) compared with the other strategies (aripiprazole = €36,328 and olanzapine = €19,957). Quetiapine presents the higher efficacy (QALY) compared with the alternatives (quetiapine = 3.551, risperidone = 3.534, aripiprazole = 3.528 and olanzapine = 3.525). With these results one can emphasize that quetiapine or risperidone treatment is dominant with the cost-effectiveness ratio (CER) of 3819 and 3706, respectively, versus aripiprazole or olanzapine groups (CER 10,297 and 5,662 respectively). The incremental CER (quetiapine vs. risperidone) is €27,322 per QALY. CONCLUSIONS: The results of cost-effectiveness illustrate that quetiapine is dominant compared with aripiprazole or olanzapine. Also quetiapine therapy is within willingness to pay threshold in case of risperidone substitution in Russian patients with bipolar disorder who are initiating atypical antipsychotics therapy. 
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ONCE-A-DAY EXTENDED-RELEASE VERSUS TWO-TIMES-DAILY IMMEDIATE-RELEASE METHYLPHENIDATE FOR THE TREATMENT OF ADHD -A COST MINIMIZATION STUDY
OBJECTIVES:
Attention Deficit/Hyperactivity Disorder (ADHD) is a neurobehavioral disorder and one of the most prevalent chronic health problems affecting school-age children, representing a costly major public health problem. Keeping in view, the substantial economic burden, the objective of this study was to conduct a cost-minimization analysis of once-a-day extended-release (ER) versus two-times-daily immediate-release (IR) methylphenidate for the treatment of ADHD patients. METHODS: Major literature databases were systematically searched to identify appropriate randomized clinical trials and meta-analyses to obtain costs associated with both the alternative formulations from a payers (third party) perspective. Medical costs included cost of drug, cost of assessments, cost of non-compliance, cost of injuries/accidents and cost of inschool administration and were obtained from published literature. All costs were adjusted to 2012 USD using consumer price index. The expected outcome was considered to be the same for both the formulations and a cost minimization analysis was performed using a decision tree approach. Multiple one-way sensitivity analyses were performed on all cost variables to evaluate the robustness of the results. RESULTS: The ER regimen of methylphenidate resulted in a total annual cost of $4685 per patient which was less costly as compared to the IR regimen that resulted in a total annual cost of $9524 per patient for the treatment of ADHD. One-way sensitivity analyses results were consistent. CONCLUSIONS: In our study Methylphenidate ER had 50.81% less annual economic burden as compared to the IR regimen for the treatment of ADHD patients.
PMH41
COST-UTILITY OF TWO SHORT-TERM PSYCHOTHERAPIES IN THE TREATMENT OF DEPRESSIVE AND ANXIETY DISORDERS DURING A THREE-YEAR FOLLOW-UP
Maljanen T 1 , Härkänen T 2 , Virtala E 2 , Lindfors O 2 , Tillman P 3 , Knekt P 2 1 The Social Insurance Institution, Helsinki, Finland, 2 National Institute for Health and Welfare, Helsinki, Finland, 3 The Social Insurance Institution, Turku, Finland OBJECTIVES: Different types of psychotherapy, alone or together with pharmaceuticals, are used extensively in the treatment of depressive and anxiety disorders. However, only a few studies thus far have addressed the costutility of different psychotherapies. The aim of this study is to compare the direct health care costs and the quality of life of persons who have suffered from depression or anxiety and have been treated either with short-term psychodynamic psychotherapy (SPP) or solution-focused therapy (SFT). The follow-up period was three years. METHODS: A total of 198 outpatients aged 20-45 years suffering from mood or anxiety disorder were randomized to SPP or SFT. Patients' quality of life was assessed using Chubon's Life Situation Survey (LSS). The assessments took place at baseline and at 7, 12 and 36 months after the start of the therapy. All direct costs due to mental health problems incurred during the three-year follow-up period were taken into account in the analysis. RESULTS: During the first 7 months patients' quality of life improved considerably, with mean LSS scores increasing from about 79 to about 93 in both groups. This change was also statistically significant. After the 7 th month some minor improvements continued to be observed in quality of life. At the end of the follow-up period the mean LSS scores were in both groups somewhat below 100, a threshold for very good life quality. The differences between the two groups were very small at every measurement point and not statistically significant. The direct costs were about equal in both groups. The small positive changes observed in the quality of life after the 7 th month were at least partly due to auxiliary treatments whose costs were much higher than the costs of SPP or SFT. CONCLUSIONS: There is little appreciable difference in cost-utility between SPP and SFT.
PMH42 HEALTH CARE AND SOCIAL SERVICE USE AND COST IN DEPRESSED AFRICAN AMERICAN ELDERS: RESULTS FROM THE BEAT THE BLUES RANDOMIZED CLINICAL TRIAL
Pizzi LT 1 , Jutkowitz E 2 , Frick KD 3 , Suh DC 4 , Prioli KM 1 , Gitlin L 5 1 Thomas Jefferson University, Philadelphia, PA, USA, 2 University of Minnesota, Minneapolis, MN, USA, 3 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 4 Chung-Ang University, Seoul, South Korea, 5 Johns Hopkins University, Baltimore, MD, USA OBJECTIVES: To report health care and social service costs from a trial of nonpharmacologic depression support program in older African Americans, Beat the Blues (BTB). METHODS: Two-group randomized design in which the BTB group received the program and the control group did not receive the program. BTB employed licensed senior center social workers to meet with participants (up to 10 sessions). Components of BTB were depression education, care management, stress reduction, referrals and linkages, and behavioral activation. Both groups were followed for 4 months. Service use and costs at each time point included health care use for depression (outpatient calls and visits to physician, emergency department visits, hospitalizations), medications, alternative approaches to managing depression (massage, acupuncture), paid caregiving (homemaker, home health aide, and visiting nurse), and social services (meals, transportation, and social worker support). RESULTS: A total of 129 subjects were randomized (68 BTB, 61 wait-list control); the average age was 68.3 years, most were female (77.9%), not married (90.4%), not employed (92%), and had an average of 6.4 health conditions (range 1-19). In both groups, costs for health care use for depression and alternative approaches to managing depression were similar at baseline. Medication costs for BTB decreased from $210 at baseline to $159 at 4 months, whereas in the wait-list control group, medication costs remained roughly constant ($186 at baseline and $197 at 4 months). Both groups experienced a decrease in paid caregiving costs ($69 in the BTB group vs. $39 in the wait-list control group). The BTB group experienced an overall cost decrease of $112 versus $19 in the wait-list control group over the 4 months. CONCLUSIONS: Decreases in medication and caregiving costs resulted in a net lower cost in the BTB group during observation period. Larger scale translational studies are needed to understand the extent to which BTB influences specific types of costs. 
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PMH43 USE OF A DECISION TREE MODEL TO ESTIMATE THE ECONOMIC BENEFITS OF REDUCING SCHIZOPHRENIA ILLNESS RELAPSE
OBJECTIVES:
To quantify the direct medical resources used and the corresponding burden of disease in the treatment of patients with schizophrenia. Because low-frequency administration (LFA) of risperidone guarantees adherence during treatment intervals and offers fewer opportunities to discontinue, adherence and persistence were assumed to improve, thereby reducing relapses of major symptoms. METHODS: A decision tree model including Markov processes with monthly cycles and a five-year maximum timeframe was constructed. Costs were adapted from the literature and discounted at a 3% annual rate. The population is a demographically homogeneous cohort of patients with schizophrenia, differentiated by initial V A L U E I N H E A L T H 1 6 ( 2 0 1 3 ) A 1 -A 2 9 8 A63 disease severity (mildly ill, moderately ill, and severely ill). Treatment parameters are estimated using published information for once-daily risperidone standard oral therapy (RIS-SOT) and once-monthly risperidone long-acting injection (RIS-LAI) with LFA therapy characteristics derived from observed study trends. One-year and five-year results are expressed as discounted direct medical costs and mean number of relapses per patient (inpatient, outpatient, total) and are estimated for LFA therapies given at three, six, and nine month intervals. RESULTS: The one-year results show that LFA therapy every 3 months (LFA-3) ($6,088) is less costly than either RIS-SOT ($10,721) or RIS-LAI ($9,450) with similar trends in the 5-year results. Moreover, the model predicts that LFA-3 versus RIS-SOT versus RIS LAI therapy will reduce costly inpatient relapses (0.16 vs. 0.51 vs. 0.41). Extending the interval to six (LFA-6) and nine (LFA-9) months resulted in further reductions in relapse and costs. Limitations include the fact that LFA therapeutic options are hypothetical and do not yet exist and limited applicability to compare one antipsychotic agent versus another as only risperidone therapy is evaluated. CONCLUSIONS: These study results have quantified the potential health state improvements and potential direct medical cost savings achievable with the development and use of LFA medication delivery technologies.
PMH44 THE SITUATION OF THE FAMILIES WITH AUTISTIC CHILDREN IN HUNGARY
Tobak O 1 , Boncz I 2 , Lampek K 2 1 University of Szeged, Szeged, Hungary, 2 University of Pécs, Pécs, Hungary OBJECTIVES: To examine the circumstances of the recognition of the autism, the problems in connection with the condition of the child as well as the opportunities, deficiencies of the support. METHODS: During the research as the first step the Autistic Association and its member organizations were selected. As the second step the families were reached through them. A total of 358 postal examinational questionnaires were sent; the interviewers visited 312 families. During my analysis the data of the samples between year 0-18 were used (276 people). The process of the data was completed by SPSS program. RESULTS: The first symptoms of autism are perceived foremost by the parents that is followed by an at least 2 years period till the diagnosis. Only 30% of the children speak well, only 59% of the parents always understand them. The 38% of children have slight or severe insomnia. A total of 84% of the children have frequent or permanent behavioural disorders. Due to the child's autism the families are isolated; 40% of the parents have been unemployed since the birth of their child. The assistance or communication between the concerned families is incidental (5%). The 36% of the parents experienced discrimination in the field of health care. The care of people with disabilities lacks from the health visitors' graduate training that makes early recognition and the care more difficult. CONCLUSIONS: There is no comprehensive strategy in Hungary for the solution of the problems of the families raising autistic children. Developing a filtering system is necessary which would decrease the time span between the recognition and the diagnose. Our other goal is to build a comprehensive training system to broaden the knowledge of the health professionals.
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CONSEQUENCES OF THE REDUCTION OF ALCOHOL CONSUMPTION ON PATIENT'S REPORTED OUTCOMES WITH THE USE OF NALMEFENE
François C 1 , Rahhali N 1 , Chalem Y 1 , Torup L 2 , Sorensen P 2 , Luquiens A 3 , Aubin HJ 3 1 Lundbeck S. A.S., France, 2 Lundbeck S.A.S., Valby, Denmark, 3 Assistance Publique-Hôpitaux de Paris, Villejuif, France OBJECTIVES: To evaluate the impact on alcohol-dependent patients' reported outcomes (PROs) from the as-needed use of nalmefene versus placebo in reduction of alcohol consumption. METHODS: Two 6-month randomized, double-blind, placebo-controlled, efficacy studies assessing nalmefene 18mg (base) were conducted in Europe (ESENSE 1 [NCT00811720]; ESENSE 2 [NCT00812461]). All patients took part in a motivational intervention (BRENDA) to support behavioural change and adherence to treatment. The Short Form Health Survey (SF-36), the EuroQol-5 Dimensions (EQ-5D) and the Drinker Inventory of Consequences (DrInC-2R) questionnaires were administered at baseline, weeks 12 and 24. Post-hoc analyses of the pooled subgroup of patients with a high drinking risk level (men:>60 g/day; women:>40 g/day) assessed change from baseline using mixed models repeated measures. RESULTS: At baseline, the sample comprised 641 patients: 322 in the placebo group, 319 in the nalmefene group. The SF-36 Mental Component Score (MCS) and the EQ-5D health state score were 40.9±12.6 and 67.9±17.2 in the placebo group; 40.9±11.9 and 68.9±17.7 in the nalmefene group. The MCS improvement at week 24 was significantly correlated to HDD (Heavy Drinking Day) and TAC (Total Alcohol Consumption) reduction and was significantly larger for the nalmefene group compared to placebo (p=0.0008): the means change from baseline were 5.74±0.79 and 2.65±0.78 in the nalmefene and placebo groups respectively. For the EQ-5D, the mean change from baseline for nalmefene compared to placebo for the health state score and the utility index score was 3.46 (p=0.0124) and 0.03 points (p=0.0445) respectively. The mean DrInC-2R total score change from baseline to week 24 was significantly correlated to HDD and TAC reduction. The improvement, indicating less alcohol-related problems, was significantly larger with nalmefene (17.86±1.31) than for placebo (14.64±1.30) (p=0.0292). CONCLUSIONS: As-needed use of nalmefene for reduction of alcohol consumption leads to statistically significantly larger improvements of alcohol dependent patients' PROs versus placebo. OBJECTIVES: Complete qualitative concept elicitation (CE) and cognitive interviews leading to preliminary development of a patient-reported outcome (PRO) measure to assess treatment benefit in major depressive disorder (MDD) clinical trials. METHODS: Qualitative interviews were conducted with adult MDD patients in the US who recently experienced a major depressive event. All participants had a Hamilton Depression Rating Scale (HAM-D) total score >18 at screening. Experienced interviewers conducted CE and cognitive interview sessions using semi-structured interview guides. The CE interview guide was used to elicit spontaneous reports of symptom experiences along with probing to further explore and confirm concepts. The cognitive interview guide was developed to evaluate concept relevance, understandability, and structure of the draft items, and to facilitate further instrument refinement. All interview sessions were audio recorded and transcribed. The CE interviews were coded for qualitative content analysis using Atlas.ti, and the cognitive interview transcripts were summarized in cognitive report tables. RESULTS: Forty patients [mean age: 46.2; 67.5% female; 45.0% white (non-Hispanic)] participated in the CE interviews. Mean (SD) HAM-D total score of the participants was 24.4 (4.3). A total of 3,022 symptom codes, representing 91 different concepts were derived from the transcripts. Data from the CE interviews was considered alongside existing literature and clinical expert opinion during an item-generation meeting, leading to development of a 36-item measure with a 5-point response scale. Subsequently, fifteen patients participated in three waves of cognitive interviews, during which, one item was removed and four others were modified. CONCLUSIONS: The S-MDD is a 35-item PRO measure intended for use as an endpoint in MDD clinical trials to support medical product labeling. It was developed in accordance with the FDAs PRO Guidance and best practices. Qualitative interviews have provided evidence for content validity. Future quantitative studies will confirm the S-MDD's measurement properties and support FDA qualification.
PMH46 QUALITATIVE DEVELOPMENT AND COGNITIVE EVALUATION OF THE SYMPTOMS OF MAJOR DEPRESSIVE DISORDER (S-MDD), A CONSORTIUM-DEVELOPED PATIENT REPORTED OUTCOME MEASURE
PMH47 ESTIMATING THE ASSOCIATION BETWEEN QT PROLONGATION AND SSRI UTILIZATION FROM THE FDA'S ADVERSE EVENT REPORTS
Guo J 1 , Guo JJ 1 , Kelton CM 2 , Wigle PR 1 1 University of Cincinnati College of Pharmacy, Cincinnati, OH, USA, 2 University of Cincinnati College of Business, Cincinnati, OH, USA Citalopram (Celexa ® ) is in the selective serotonin reuptake inhibitor (SSRI) class of antidepressants. It is taken orally. Citalopram has been linked to both QT prolongation and Torsade de pointes (TdP), and these risks may be dose related. OBJECTIVES: To analyze the association between QT prolongation and TdP adverse events and the utilization of citalopram and other SSRIs. METHODS: This retrospective, descriptive study used the U.S. FDA Adverse Event Reporting System (FAERS) database. The database included 7,840,225 adverse events associated with SSRI drugs from 1997 fourth quarter to 2011 third quarter. The number of reported QT-prolongation and TdP cases associated with each study drug was calculated over time. Furthermore, for each case, dosage of the drug, when available in the report, was noted. RESULTS: A total of 1192 reported cases of QT prolongation and TdP were associated with SSRI drugs over the 14-year study period. Only 18% (219) of the adverse event reports were related specifically to citalopram, while the rest were related to other SSRI drugs. There were 911 reports for women, 252 for men, and 29 reports without gender information. The rate of QT prolongation and TdP associated with dosages of 20 mg, 40 mg, and 60 mg of citalopram per day were 39%, 21%, and 2%, respectively. However, the percentage of reports without dosage information was 37%, so we were unable to draw any conclusions regarding dosage-related events. CONCLUSIONS: The results confirmed an association between the use of citalopram with QT prolongation and TdP. Furthermore, the association was not limited to citalopram alone but was widespread across the SSRIs. There were more adverse events observed for women than for men. Dose dependency was not established in this study. Future studies are warranted. 
PMH48 USING TRANSLATABILITY ASSESSMENT TO REFINE A PATIENT-REPORTED OUTCOME (PRO) MEASURE DURING THE DEVELOPMENT PROCESS
OBJECTIVES:
To show how translatability assessment during the patientreported outcome (PRO) measure development process can be used to identify areas where wording changes are needed to improve and refine the measure. METHODS: A translatability assessment was conducted on a new 35-item PRO measure called Symptoms of Major Depressive Disorder (S-MDD) for evaluating treatment benefits in MDD. Five different languages were selected (French, Spanish, German, Chinese, and Russian). Each PRO item was reviewed and assigned a difficulty rating between 1 (no difficulty) and 5 (extreme difficulty) by an experienced translation consultant in each language. The difficult concepts for translation were compared to the problematic items for patient comprehension (from cognitive interviews) to identify difficult items for both translation and patient comprehension. RESULTS: Three items of the 35-item S-MDD showed difficulty in patient comprehension and in the ability to accurately translate the concept. Due to the convergence of these two problematic findings during the PRO development, the item "how difficult was it for you to keep your mind free of worrying thoughts?" was changed to "how difficult was it for you to
